

While the true prevalence of HPP remains unknown, estimates suggest it occurs in ~1 in 5,685 people\* –

**MANY OF WHOM REMAIN UNDIAGNOSED<sup>1-4</sup>**



Rethink HPP diagnosis by earlier recognition of hypophosphatasia signs and symptoms and the impact of persistently low ALP adjusted for age and sex<sup>5</sup>

\*Prevalence data has been calculated based on information presented in Tornero C, et al. 2020.<sup>1</sup>

ALP, alkaline phosphatase; HPP, hypophosphatasia.

**1.** Tornero C, et al. *Orphanet J Rare Dis.* 2020;15(1):51. **2.** Rockman-Greenberg C. *Pediatr Endocrinol Rev.* 2013;10(Suppl 2):380–388. **3.** NORD. Hypophosphatasia. Available at: <https://rarediseases.org/rare-diseases/hypophosphatasia/#complete-report> (Accessed February 2025). **4.** Tournis S, et al. *J Clin Med.* 2021;10(23):5676. **5.** Khan AA, et al. *Osteoporos Int.* 2024;35(3):431–438.

The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc. This material is intended for healthcare professionals only. © 2025 Alexion Pharmaceuticals, Inc. All rights reserved.  
GL/UNB-H/0019 | February 2025

**ALEXION**<sup>®</sup>  
AstraZeneca Rare Disease